R Tripeny Biography and Net Worth

Director of Mesa Laboratories

During his 36-year career with Corning, Incorporated, Tony Tripeny held various, progressive leadership roles in the areas of corporate accounting and finance, including Executive Vice President, Chief Financial Officer and Senior Vice President, Corporate Controller and Principal Accounting Officer. He has significant operational, strategy, and M&A experience, extensive knowledge of the manufacturing, technology, and life sciences industries, and a background in international corporate accounting. Mr. Tripeny has a leadership style characterized by his ability to be steady, adaptable, and action-oriented during times of volatility and possesses a proven track record of recruiting and mentoring diverse talent. He received a bachelor’s degree in economics from the University of Pennsylvania’s Wharton School of Business and is a member of the Financial Executives Institute and the Institute of Management Accounting.

What is R Tony Tripeny's net worth?: The estimated net worth of R Tony Tripeny is at least $477.29 thousand as of March 10th, 2026. Tripeny owns 5,398 shares of Mesa Laboratories stock worth more than $477,291 as of March 31st. This net worth approximation does not reflect any other assets that Tripeny may own. Learn More about R Tony Tripeny's net worth.
How do I contact R Tony Tripeny?: The corporate mailing address for Tripeny and other Mesa Laboratories executives is 12100 W 6TH AVE, LAKEWOOD CO, 80228. Mesa Laboratories can also be reached via phone at (303) 987-8000 and via email at [email protected]. Learn More on R Tony Tripeny's contact information.
Has R Tony Tripeny been buying or selling shares of Mesa Laboratories?: During the last ninety days, R Tony Tripeny has bought $99,940.00 of Mesa Laboratories stock. Most recently, on Tuesday, March 10th, R Tony Tripeny bought 1,315 shares of Mesa Laboratories stock. The stock was acquired at an average cost of $76.00 per share, with a total value of $99,940.00. Following the completion of the transaction, the director now directly owns 5,398 shares of the company's stock, valued at $410,248. Learn More on R Tony Tripeny's trading history.
Who are Mesa Laboratories' active insiders?: Mesa Laboratories' insider roster includes Brian Archbold (SVP), Mark Capone (Director), Gregory DiNoia (SVP), Evan Guillemin (Director), David Kelly (Director), Gary Owens (CEO), John Sakys (CFO), John Schmieder (Director), John Sullivan (Director), and R Tripeny (Director). Learn More on Mesa Laboratories' active insiders.
Are insiders buying or selling shares of Mesa Laboratories?: During the last twelve months, Mesa Laboratories insiders bought shares 3 times. They purchased a total of 6,116 shares worth more than $452,076.35. During the last twelve months, insiders at the medical instruments supplier sold shares 3 times. They sold a total of 3,053 shares worth more than $296,507.36. The most recent insider tranaction occured on March, 10th when Director Mark Christopher Capone bought 1,301 shares worth more than $99,331.35. Insiders at Mesa Laboratories own 4.9% of the company. Learn More about insider trades at Mesa Laboratories.
Information on this page was last updated on 3/10/2026.

R Tony Tripeny Insider Trading History at Mesa Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2026	Buy	1,315	$76.00	$99,940.00	5,398

R Tony Tripeny Buying and Selling Activity at Mesa Laboratories

Mesa Laboratories Company Overview

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Today's Range

Now: $88.42

$85.96

$88.88

50 Day Range

MA: $86.38

$73.23

$96.57

2 Week Range

Now: $88.42

$55.45

$131.20

Volume

99,257 shs

Average Volume

109,610 shs

Market Capitalization

$488.08 million

P/E Ratio

138.16

Dividend Yield

0.78%

Beta

0.85